MoonLake Immunotherapeutics (MLTX) Non Operating Income (2021 - 2022)
MoonLake Immunotherapeutics' (MLTX) quarterly Non Operating Income came in at $7774.0 in Q1 2022, down 56.36% year-on-year from $17815.0 in Q1 2021, and up 244.75% quarter-over-quarter from $2255.0 in Q4 2021.
MoonLake Immunotherapeutics (MLTX) Non Operating Income (2021 - 2022) Analysis & Trends
MoonLake Immunotherapeutics' Non Operating Income history runs 2 years deep, the most recent figure standing at $7774.0 for Q1 2022.
- On a quarterly basis, Non Operating Income fell 56.36% year-over-year to $7774.0 in Q1 2022; TTM through Mar 2022 was $17650.0, a N/A change from a year earlier, with the FY2021 full-year figure at $27691.0, up 85.63% from the prior year.
- Non Operating Income climbed to $7774.0 in Q1 2022 per MLTX's latest filing, from $2255.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $17815.0 in Q1 2021 and bottomed at $1481.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -8.59 Mn |
| 10 | MoonLake Immunotherapeutics | 1.35 Bn | 991.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 7,774.00 |
| Dec 31, 2021 | 2,255.00 |
| Sep 30, 2021 | 1,481.00 |
| Jun 30, 2021 | 6,140.00 |
| Mar 31, 2021 | 17,815.00 |